Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q61126288 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241221010726.0 | ||
| 008 | 241221nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q61126288 | ||
| 024 | ‡a 0000-0001-8958-0694 ‡2 orcid | ||
| 035 | ‡a (OCoLC)Q61126288 | ||
| 100 | 0 | ‡a Isabel Alvarez ‡c researcher ORCID ID = 0000-0001-8958-0694 ‡9 en | |
| 375 | ‡a 2 ‡2 iso5218 | ||
| 400 | 0 | ‡a Isabel Alvarez ‡c onderzoeker ‡9 nl | |
| 670 | ‡a Author's A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology | ||
| 670 | ‡a Author's A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). | ||
| 670 | ‡a Author's A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study | ||
| 670 | ‡a Author's Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-the Evaluating Treatment With Neoadjuvant Abraxane | ||
| 670 | ‡a Author's Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-the Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial | ||
| 670 | ‡a Author's Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients | ||
| 670 | ‡a Author's Long-Term Follow-Up of the Intergroup Exemestane Study | ||
| 670 | ‡a Author's Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. | ||
| 670 | ‡a Author's Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study | ||
| 670 | ‡a Author's Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study | ||
| 670 | ‡a Author's Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy | ||
| 670 | ‡a Author's Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer | ||
| 670 | ‡a Author's SEOM clinical guidelines in metastatic breast cancer 2015. | ||
| 670 | ‡a Author's The Allele of rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin | ||
| 670 | ‡a Author's Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. | ||
| 909 | ‡a (orcid) 0000000189580694 ‡9 1 | ||
| 919 | ‡a nabpaclitaxelinmetastaticbreastcancerdefiningthebestpatientprofile ‡A Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. ‡9 1 | ||
| 919 | ‡a contextualizingpertuzumabapprovalinthetreatmentofher2positivebreastcancerpatients ‡A Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients ‡9 1 | ||
| 919 | ‡a longtermfollowupoftheintergroupexemestanestudy ‡A Long-Term Follow-Up of the Intergroup Exemestane Study ‡9 1 | ||
| 919 | ‡a definitionforaggressivediseaseinpatientswithher2negativemetastaticbreastcanceranexpertconsensusofthespanishsocietyofmedicaloncology ‡A A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology ‡9 1 | ||
| 919 | ‡a definitionforaggressivediseaseinpatientswithher2negativemetastaticbreastcanceranexpertconsensusofthespanishsocietyofmedicaloncologyseom ‡A A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). ‡9 1 | ||
| 919 | ‡a phase2trialofneoadjuvantmetforminincombinationwithtrastuzumabandchemotherapyinwomenwithearlyher2positivebreastcancerthemettenstudy ‡A A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study ‡9 1 | ||
| 919 | ‡a comparingneoadjuvantnabpaclitaxelvspaclitaxelbothfollowedbyanthracyclineregimensinwomenwitherbb2her2negativebreastcancertheevaluatingtreatmentwithneoadjuvantabraxane ‡A Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-the Evaluating Treatment With Neoadjuvant Abraxane ‡9 1 | ||
| 919 | ‡a comparingneoadjuvantnabpaclitaxelvspaclitaxelbothfollowedbyanthracyclineregimensinwomenwitherbb2her2negativebreastcancertheevaluatingtreatmentwithneoadjuvantabraxaneetnatrialarandomizedphase3clinicaltrial ‡A Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-the Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial ‡9 1 | ||
| 919 | ‡a treatmentinnovationsformetastaticbreastcancernanoparticlealbuminboundnabtechnologytargetedtotumors ‡A Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. ‡9 1 | ||
| 919 | ‡a alleleofrs11212617associateswithhigherpathologicalcompleteremissionrateinbreastcancerpatientstreatedwithneoadjuvantmetformin ‡A The Allele of rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin ‡9 1 | ||
| 919 | ‡a seomclinicalguidelinesinmetastaticbreastcancer ‡A SEOM clinical guidelines in metastatic breast cancer 2015. ‡9 1 | ||
| 919 | ‡a reviewofconceptsintherapeuticdecisionmakinginher2negativeluminalmetastaticbreastcancer ‡A Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer ‡9 1 | ||
| 919 | ‡a prognosticroleforthederivedneutrophiltolymphocyteratioinearlybreastcancerageicam9906substudy ‡A Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy ‡9 1 | ||
| 919 | ‡a prognosticabilityofendopredictcomparedtoresearchbasedversionsofthepam50riskofrecurrencerorscoresinnodepositiveestrogenreceptorpositiveandher2negativebreastcancerageicam9906substudy ‡A Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study ‡9 1 | ||
| 919 | ‡a phase3evaluatingtheadditionoffulvestrantftoanastrozoleaasadjuvanttherapyinpostmenopausalwomenwithhormonereceptorpositiveher2negativehr+her2earlybreastcancerebcresultsfromthegeicam200610study ‡A Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study ‡9 1 | ||
| 943 | ‡a 201x ‡A 2015 ‡9 1 | ||
| 946 | ‡a a ‡9 1 | ||
| 996 | ‡2 NUKAT|n 2018091560 | ||
| 996 | ‡2 PTBNP|1669344 | ||
| 996 | ‡2 DNB|1057409936 | ||
| 996 | ‡2 SUDOC|190363428 | ||
| 996 | ‡2 PTBNP|1049466 | ||
| 996 | ‡2 LC|no2011054543 | ||
| 996 | ‡2 ISNI|0000000426868203 | ||
| 996 | ‡2 BNE|XX1585476 | ||
| 996 | ‡2 SUDOC|154968234 | ||
| 996 | ‡2 ISNI|0000000059432714 | ||
| 996 | ‡2 NTA|072276134 | ||
| 996 | ‡2 LC|no2015148849 | ||
| 996 | ‡2 BNE|XX1647757 | ||
| 996 | ‡2 DNB|105305811X | ||
| 996 | ‡2 LC|n 2019066720 | ||
| 996 | ‡2 BNE|XX4809043 | ||
| 996 | ‡2 SUDOC|22431498X | ||
| 996 | ‡2 BNE|XX1619419 | ||
| 996 | ‡2 ISNI|0000000129987003 | ||
| 996 | ‡2 ISNI|0000000059477429 | ||
| 996 | ‡2 BNE|XX872090 | ||
| 996 | ‡2 LC|no2016013789 | ||
| 996 | ‡2 ISNI|0000000382071357 | ||
| 996 | ‡2 BNE|XX1232221 | ||
| 996 | ‡2 LC|n 89601614 | ||
| 996 | ‡2 PLWABN|9814189461505606 | ||
| 996 | ‡2 LC|n 2018013069 | ||
| 996 | ‡2 BNC|981058613279706706 | ||
| 996 | ‡2 LC|nb2012024958 | ||
| 996 | ‡2 DNB|1056438843 | ||
| 996 | ‡2 CAOONL|ncf11716649 | ||
| 996 | ‡2 ISNI|0000000454927012 | ||
| 996 | ‡2 BNC|981060723415406706 | ||
| 996 | ‡2 BNF|14149413 | ||
| 996 | ‡2 BNE|XX4903786 | ||
| 996 | ‡2 DNB|1231253282 | ||
| 996 | ‡2 ARBABN|000027957 | ||
| 996 | ‡2 LC|n 2008045103 | ||
| 996 | ‡2 ISNI|0000000378056533 | ||
| 996 | ‡2 DNB|1057338206 | ||
| 996 | ‡2 ISNI|0000000447046727 | ||
| 996 | ‡2 PLWABN|9812785055405606 | ||
| 996 | ‡2 BNE|XX933176 | ||
| 996 | ‡2 LC|n 2017250140 | ||
| 996 | ‡2 BNC|981058517574706706 | ||
| 996 | ‡2 ICCU|TO0V532317 | ||
| 996 | ‡2 NUKAT|n 2014049014 | ||
| 996 | ‡2 ISNI|0000000053877376 | ||
| 996 | ‡2 LC|no2019050649 | ||
| 996 | ‡2 LC|no2023046486 | ||
| 996 | ‡2 ISNI|0000000384954567 | ||
| 996 | ‡2 CAOONL|ncf10178607 | ||
| 996 | ‡2 LC|no 97057294 | ||
| 996 | ‡2 BNE|XX5478463 | ||
| 996 | ‡2 ISNI|0000000076594432 | ||
| 996 | ‡2 BNE|XX986804 | ||
| 996 | ‡2 LC|n 2005036834 | ||
| 996 | ‡2 BNE|XX1015247 | ||
| 996 | ‡2 DNB|1093189959 | ||
| 996 | ‡2 BNE|XX1091800 | ||
| 996 | ‡2 SUDOC|183331575 | ||
| 996 | ‡2 BNE|XX1603660 | ||
| 996 | ‡2 BNF|17155513 | ||
| 996 | ‡2 BNC|981058608985306706 | ||
| 996 | ‡2 LC|no2004059839 | ||
| 996 | ‡2 BNE|XX6156409 | ||
| 996 | ‡2 BNE|XX5066550 | ||
| 996 | ‡2 BNE|XX1773019 | ||
| 996 | ‡2 ISNI|0000000060417845 | ||
| 996 | ‡2 ISNI|0000000118937166 | ||
| 996 | ‡2 PTBNP|1458251 | ||
| 996 | ‡2 SUDOC|191222844 | ||
| 996 | ‡2 BNE|XX5564415 | ||
| 996 | ‡2 ISNI|0000000059490375 | ||
| 996 | ‡2 BNE|XX1316624 | ||
| 996 | ‡2 J9U|987007339417205171 | ||
| 996 | ‡2 BNE|XX1318208 | ||
| 996 | ‡2 DNB|1056496584 | ||
| 996 | ‡2 RERO|A004021692 | ||
| 996 | ‡2 BNE|XX1177027 | ||
| 996 | ‡2 SUDOC|169009394 | ||
| 996 | ‡2 BNE|XX1667222 | ||
| 996 | ‡2 LC|n 85815397 | ||
| 996 | ‡2 BNC|981058610855806706 | ||
| 996 | ‡2 BIBSYS|90146184 | ||
| 996 | ‡2 BLBNB|001420903 | ||
| 996 | ‡2 ISNI|0000000455179044 | ||
| 996 | ‡2 NUKAT|nx2023988793 | ||
| 996 | ‡2 BNC|981058599238006706 | ||
| 996 | ‡2 DNB|144040360 | ||
| 996 | ‡2 DNB|1163559431 | ||
| 996 | ‡2 LC|n 87917869 | ||
| 996 | ‡2 PLWABN|9810642764905606 | ||
| 996 | ‡2 RERO|A004021635 | ||
| 996 | ‡2 DNB|13059900X | ||
| 996 | ‡2 SUDOC|085711071 | ||
| 996 | ‡2 BNE|XX1432224 | ||
| 996 | ‡2 BNE|XX857444 | ||
| 996 | ‡2 PTBNP|1777308 | ||
| 996 | ‡2 BNC|981058509947306706 | ||
| 996 | ‡2 BNC|981058524513406706 | ||
| 996 | ‡2 ISNI|0000000029308210 | ||
| 996 | ‡2 PTBNP|1667749 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
